Drugs / DRINABANT
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00380302 | Sep 2006 → Jul 2007 | Alzheimer disease | Sanofi | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00439634 | Feb 2007 → Sep 2009 | schizophrenia | Sanofi | Terminated | No outcome recorded |
| Phase 2 | NCT00345410 | Jun 2006 → Jun 2007 | hyperlipidemia, obesity disorder | Sanofi | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DRINABANT | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545166 ↗ |
| Known as | AVE1625 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00380302 ↗ |
| Action | Inhibit | “AVE1625 is a new potent and selective cannabinoid 1 (CB1) antagonist in clinical development for the treatment of cognitive impairment in patients diagnosed with schizophrenia.” NCT00439634 ↗1“Cannabinoid CB1 receptor antagonist” CHEMBL3545166 ↗ |
| Modality | Small molecule | — CHEMBL3545166 ↗ |
| Route | Oral | “oral administration” NCT00439634 ↗ |
| Target | CNR1 | “Cannabinoid CB1 receptor antagonist” CHEMBL3545166 ↗ |